Clinical Trial Update: Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating hydroxychloroquine with carboplatin, paclitaxel, and bevacizumab in recurrent advanced non-small cell lung cancer; the study was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Hydroxychloroquine (hydroxychloroquine)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Medicine and Dentistry of New Jersey | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2013-11-25